Although most ER-positive/HER2-negative (ER+/HER2−) breast cancers are associated with good prognosis, around one third of patients progress and develop late recurrences, sometimes even decades after initial diagnosis and treatment [2,3]. This evidence concerns the gene ERBB2 and breast carcinoma.